Immunovia
0,819
SEK
-2,62 %
IMMNOV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
-2,62%
+34,04%
-3,65%
+14,81%
-6,96%
-6,01%
-97,78%
-98,66%
-94,02%
immunovia.com
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Omsætning
1,58 mio.
EBIT %
-18.763,29 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
IMMNOV
Daglig lav / høj pris
0,74 / 0,83
SEK
Markedsværdi
138,99 mio. SEK
Aktieomsætning
4,58 mio. SEK
Volumen
5,9 mio.
Seneste videoer
Finanskalender
Årsrapport
25.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Försäkringsbolaget Avanza Pension | 11,6 % | 11,6 % |
| Vincent Saldell | 3,5 % | 3,5 % |
| Nordnet Pensionsförsäkring AB | 1,8 % | 1,8 % |
| Carl Borrebaeck | 1,1 % | 1,1 % |
| Jens Henrik Lensen | 1,0 % | 1,0 % |
| Simon Borsos | 1,0 % | 1,0 % |
| Vator Securities AB | 0,9 % | 0,9 % |
| Försäkringsaktiebolaget Skandia | 0,9 % | 0,9 % |
| Ghanem Georges Chouba | 0,8 % | 0,8 % |
| Sten Jonsson | 0,8 % | 0,8 % |
ViserAlle indholdstyper
Immunovia AB: Immunovia Publishes Interim Report for January-September 2024
Immunovia AB: Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools